Close Menu

NEW YORK – Roche said on Monday that the European Commission granted conditional marketing authorization to entrectinib (Rozlytrek) for patients with advanced, metastatic, or unresectable NTRK fusion-positive solid cancers, who have not been previously treated with an NTRK inhibitor and have no other treatment options. The EC also conditionally authorized entrectinib for ROS1-positive, advanced non-small cell lung cancer patients who have not received other ROS1 inhibitors.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.